Abstract
Ken Alibek was for 17 years a leader in Biopreparat, the Soviet Union's top secret agency involved in developing and stockpiling the most lethal bacteria, viruses, and toxins in the history of mankind before he defected with his family to the United States in 1992. Very contrite when he discovered he had been misled to believe that his efforts had been essential to the survival of his homeland, Alibek has become active sounding an alarm about, among other things, thousands of unemployed Russian scientists who have been seeking survival by selling their destructive expertise to rouge states and bioterrorists. Working full time in devising protective measures that might help control the damaging effects of terrorist attacks, Alibek has placed strong emphasis on stimulating nonspecific immunities of victims mainly with interleukins and other cytokines. A more productive alternative would be giving mitogens such as PHA and PWM to reinforce vaccine and antibiotic actions, at the same time stimulating protective immune, myelopoietic, and lymphopoietic responses. A key objective would be to find an effective management for the dreaded viral hemorrhagic fevers. Using Ebola infection as an experimental model, Yang et al. have shown that...Continue Reading
References
Apr 14, 1976·Biochimica Et Biophysica Acta·K YokoyamaT Osawa
Jan 1, 1992·Journal of Clinical Pharmacology·M S Mitchell
Jul 19, 1990·Nature·J R Gordon, S J Galli
Jun 1, 1988·Immunology Today·S H Kaufmann
Jun 1, 1972·Transplantation·W RosenauM Goldberg
Aug 27, 1974·Biochemistry·M J Waxdal
Sep 1, 1969·Proceedings of the National Academy of Sciences of the United States of America·M L GoldbergG C Burke
Jun 1, 1970·Proceedings of the Society for Experimental Biology and Medicine·M L GoldbergH D Moon
Apr 15, 1969·Experientia·D A Rigas, V V Tisdale
Jan 1, 1993·Annual Review of Immunology·S H Kaufmann
Mar 7, 1998·Science·Z YangG J Nabel
May 10, 2000·Cancer Biotherapy & Radiopharmaceuticals·B M Wimer, P L Mann
May 10, 2000·Cancer Biotherapy & Radiopharmaceuticals·B M Wimer
Jun 13, 2000·Cancer Biotherapy & Radiopharmaceuticals·B M Wimer
Jun 1, 1997·Cancer Biotherapy & Radiopharmaceuticals·B M Wimer
Aug 10, 2000·Nature Medicine·Z Y YangG J Nabel
Feb 24, 2001·Cancer Biotherapy & Radiopharmaceuticals·B M Wimer, P L Mann
Nov 21, 1964·Lancet·P FARNESH FANGER